Sanofi (SNY)
(Delayed Data from NSDQ)
$48.42 USD
-0.25 (-0.51%)
Updated May 20, 2024 04:00 PM ET
After-Market: $48.45 +0.03 (0.06%) 7:22 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$48.42 USD
-0.25 (-0.51%)
Updated May 20, 2024 04:00 PM ET
After-Market: $48.45 +0.03 (0.06%) 7:22 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Zacks News
Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals
by Zacks Equity Research
After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.
Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data
by Arpita Dutt
Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.
Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline
by Zacks Equity Research
We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017.
Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis
by Zacks Equity Research
Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that the FDA has approved their pipeline candidate sarilumab to be marketed under the trade name of Kevzara.
Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog
by Zacks Equity Research
Sanofi (SNY) recently announced that the CHMP has given a positive opinion, recommending marketing approval to a biosimilar version of Humalog (insulin lispro).
Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings?
by Arpita Dutt
Merck (MRK) and Sanofi (SNY) are both Zacks Rank #2 (Buy) stocks. Which company looks better-positioned for the remainder of the year?
Pharma Stock Roundup: J&J's Pharma Pipeline Update, Shire's HAE Data & More
by Arpita Dutt
This week, industry bellwether J&J (JNJ) provided a look at its pharma pipeline while Shire was up on HAE data.
Immune Design (IMDZ) Posts Narrower-than-Expected Loss in Q1
by Zacks Equity Research
Immune Design Corp. (IMDZ) reported first-quarter 2017 loss of 50 cents per share, narrower than the Zacks Consensus Estimate of a loss of 62 cents and also a year-ago loss of 61 cents.
Bull of the Day: Regeneron (REGN)
by Kevin Cook
Shares launched 25% recently as Kevzara and the launch of Dupixent are expected to reignite sales growth
AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher
by Zacks Equity Research
AstraZeneca PLC (AZN) shares rose above 9% in the last trading session.
Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan
by Zacks Equity Research
Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period
Alnylam (ALNY) Q1 Loss Wider than Expected, Revenues Up Y/Y
by Zacks Equity Research
Alnylam Pharmaceuticals, Inc. (ALNY) reported a loss of $1.25 per share in the first quarter of 2017, wider than the Zacks Consensus Estimate of a loss of $1.22 and the year-ago loss of $1.21.
Keryx (KERX) Q1 Loss Wider than Expected, Revenues Beat
by Zacks Equity Research
Keryx Biopharmaceuticals Inc. (KERX) reported first-quarter 2017 loss of 21 cents per share, narrower than the year-ago loss of 39 cents
BioMarin (BMRN) Posts Earnings in Q1, Sales Top, Stock Up
by Zacks Equity Research
BioMarin Pharmaceutical Inc. (BMRN) reported earnings of 3 cents per share in the first quarter of 2017.
Regeneron (REGN) Q1 Earnings Miss, Revenues Beat Estimates
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) reported first-quarter 2017 results wherein earnings missed estimates while revenues beat expectations.
VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents
6 FDA Events to Watch Out for in May 2017
by Arpita Dutt
Here is a look at a few important regulatory events scheduled for the month of May including the FDA's decision regarding the label expansion of Merck's (MRK) Keytruda.
Regeneron (REGN) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Regeneron Pharmaceuticals, Inc. (REGN) is scheduled to release first-quarter 2017 results on May 4, before the opening bell.
Sanofi (SNY) Q1 Earnings Top, Sales Rise Y/Y, Shares Up
by Zacks Equity Research
Sanofi (SNY) reported first-quarter 2017 earnings of 75 cents per American depositary share, which beat the Zacks Consensus Estimate of 73 cents by 2.7%.
Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate of 4 cents.
Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More
by Arpita Dutt
Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.
Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline
by Zacks Equity Research
Biotech major Amgen Inc. (AMGN) reported first-quarter 2017 earnings of $3.15 per share, beating the Zacks Consensus Estimate of $3.00 by 5% .
Lilly (LLY) Tops Q1 Earnings, Misses Sales, Shares Down
by Zacks Equity Research
Eli Lilly and Company (LLY) reported first-quarter 2017 adjusted earnings per share of 98 cents, which beat the Zacks Consensus Estimate of 96 cents by 2.1%.
Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL
by Arpita Dutt
Key highlights from the pharma sector include J&J's (JNJ) first quarter results and a CRL for Lilly's RA drug.
Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Eli Lilly and Company (LLY) will report first-quarter 2017 results on Apr 25, before the market opens.